Larvol Delta - Longitudinal-Inflammatory-Biomarker-Outcomes-and-Treatment-Persistence-With-Bimekizumab-in-a-RealWorld-Cohort

Bimzelx (bimekizumab-bkzx) - UCB

http://clinicaltrials.gov/ct2/show/NCT07497620

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next